



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

Limited Review Report

Review Report to the Board of Directors of M/s Ajooni Biotech Limited

We have reviewed the accompanying statement of Un-Audited Financial Result of **M/s. Ajooni Biotech Limited** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Half Year ended 30th Sep, 2018 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Engagement to "*Review of Interim Financial Information performed by the independent auditor of the entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.


Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Un-Audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any martial misstatement.

Date: 14-November-2018
Place: Mohali



For Harjeet Parvesh & Co.
Chartered Accountants

Firm Regn. No. 017437N


CA Suprit Kaur
Partner
M.No 424986

AJOONI BIOTECH LIMITED

CIN : U85190PB2010PLC040162

STATEMENT OF FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30.09.2018 (IN LAKHS)

PARTICULARS		Half Year Ended		Year Ended
		30.09.2018 (Unaudited)	31.03.2018 (Unaudited)	31.03.2018 (Audited)
I	Revenue From Operations	1826.06	2176.57	4237.42
II	Other Income	1.53	21.05	22.00
III	TOTAL REVENUE (I + II)	1,827.59	2,197.62	4,259.42
IV	EXPENSES:			
	Cost of Material Consumed	1949.35	1909.10	3755.44
	Purchase of Stock-In-Trade	0.00	0.00	0.00
	Change In Inventories	-286.23	-3.72	13.48
	Finance Cost	4.39	10.83	34.07
	Employee Benefit Expenses	54.79	52.77	88.15
	Depreciation and amortization	14.19	22.78	45.55
	Other Expenses	70.53	164.36	273.93
	TOTAL EXPENSES	1,807.02	2,156.11	4,210.63
V	PROFIT / (LOSS) FROM OPERATION BEFORE EXCEPTIONAL AND EXTRAORDINARY ITEMS AND TAX (III-IV)	20.57	41.52	48.79
VI	Exceptional Items	0.00	0.00	0.00
VII	PROFIT / (LOSS) BEFORE EXTRAORDINARY ITEMS AND TAX (V-VI)	20.57	41.52	48.79
VIII	Extraordinary items	0.00	0.00	0.00
IX	PROFIT / (LOSS) BEFORE TAX (VII-VIII)	20.57	41.52	48.79
X	TAX EXPENSE:			
	(1) Current Tax	0.00	13.08	13.08
	(2) Deferred Tax	0.00	-2.90	-2.90
	(3) MAT Credit	0.00	0.00	0.00
XI	NET PROFIT / (LOSS) FROM CONTINUING OPERATIONS (VII-VIII)	20.57	31.33	38.61
XII	NET PROFIT / (LOSS) FROM DISCONTINUING OPERATIONS	0.00	0.00	0.00
XIII	TAX EXPENSE OF DISCONTINUING OPERATIONS	0.00	0.00	0.00
XIV	NET PROFIT / (LOSS) FROM DISCONTINUING OPERATIONS (after Tax) (XII-XIII)	0.00	0.00	0.00
XV	Profit/Loss for the period (XI+XIV)	20.57	31.33	38.61
XVI	NET PROFIT / (LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT / (LOSS) OF ASSOCIATES (13 + 14 + 15) *	20.57	31.33	38.61
XVII	Paid-up equity share capital (Face Value of the Share shall be indicated)	585.50	585.50	585.50
XVIII	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	508.86	63.89	63.89
XIX	Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised):			
	(1) BASIC	0.35	0.54	0.66
	(2) DILUTED	0.35	0.54	0.66
XX	Earnings Per Share (after extraordinary items) (of Rs ___/- each) (not annualised):			
	(1) BASIC	0.35	0.54	0.66
	(2) DILUTED	0.35	0.54	0.66

* Applicable in the case of consolidated results.

Notes:

- The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their
- Segment Reporting is not applicable, since the company is involved in one segment only

For and on behalf of Board of Ajooni Biotech Limited
For AJOOONI BIOTECH LTD.

Place : Mohali

Date : 14.11.2018

Jasjit Singh
Director

AJOONI BIOTECH LIMITED

CIN : U85190PB2010PLC040162

STATEMENT OF ASSETS AND LIABILITIES AS ON 30.09.2018

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES	AS ON	AS ON
	30.09.2018	31.03.2018
I.EQUITY AND LIABILITIES		
(1) SHAREHOLDER'S FUND		
(A) SHARE CAPITAL	585.50	585.50
(B) RESERVES AND SURPLUS	529.43	508.86
(C) MONEY RECEIVED AGAINST SHARE WARRANTS		
SUB-TOTAL - SHAREHOLDERS' FUNDS		
(2) SHARE APPLICATION MONEY PENDING ALLOTMENT		
(3) MINORITY INTEREST *		
(4) NON CURRENT LIABILITIES		
(A) LONG TERM BORROWINGS	86.37	467.89
(B) DEFERRED TAX LIABILITIES (NET)		
(C) OTHER NON-CURRENT LIABILITIES	216.99	216.99
(D) LONG-TERM PROVISIONS		
SUB-TOTAL - NON-CURRENT LIABILITIES		
(5) CURRENT LIABILITIES		
(A) SHORT TERM BORROWINGS	61.00	-
(B) TRADE PAYABLE	153.99	115.09
(C) OTHER CURRENT LIABILITIES	12.45	22.37
(D) SHORT TERM PROVISIONS	-	13.08
SUB-TOTAL - CURRENT LIABILITIES		
TOTAL EQUITY & LIABILITIES	1,645.73	1,929.78
II.ASSETS		
(1) NON CURRENT ASSETS		
(A) FIXED ASSETS		
(i) TANGIBLE ASSETS	102.87	103.55
(B) GOODWILL ON CONSOLIDATION *		
(C) NON CURRENT INVESTMENTS	422.02	601.84
(D) DEFERRED TAX ASSETS (NET)	3.94	3.94
(E) LONG TERM LOANS & ADVANCES		
(F) OTHER NON CURRENT ASSETS	56.39	56.28
SUB-TOTAL - NON-CURRENT ASSETS		
(2) CURRENT ASSETS		
(A) CURRENT INVESTMENTS		
(B) INVENTORIES	486.14	199.90
(C) TRADE RECEIVABLES	353.22	286.17
(D) CASH AND CASH EQUIVALENTS	17.85	529.69
(E) SHORT TERM LOANS AND ADVANCES	125.36	70.05
(F) OTHER CURRENT ASSETS	77.95	78.35
SUB-TOTAL - CURRENT ASSETS		
TOTAL-ASSETS	1,645.73	1,929.78

*APPLICABLE IN THE CASE OF CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

For and on behalf of Board of Ajooni Biotech Limited

For AJOONI BIOTECH LTD.

Place : Mohali

Date : 14.11.2018

Jasjot Singh

Director

Director

DIN: 01937631